363 related articles for article (PubMed ID: 16315315)
1. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
2. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
3. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
4. Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related.
Winter AG; Dorgan C; Melton DW
Oncogene; 2005 Mar; 24(12):2110-3. PubMed ID: 15688021
[TBL] [Abstract][Full Text] [Related]
5. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
[TBL] [Abstract][Full Text] [Related]
6. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
Fan W; Zhang HL; Wu XM
Ai Zheng; 2005 Apr; 24(4):403-7. PubMed ID: 15820060
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Chen ZP; Malapetsa A; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Panasci LC
Ai Zheng; 2002 Mar; 21(3):233-9. PubMed ID: 12451985
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
10. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
12. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.
Evans E; Moggs JG; Hwang JR; Egly JM; Wood RD
EMBO J; 1997 Nov; 16(21):6559-73. PubMed ID: 9351836
[TBL] [Abstract][Full Text] [Related]
14. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
Dabholkar M; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
J Clin Invest; 1994 Aug; 94(2):703-8. PubMed ID: 8040325
[TBL] [Abstract][Full Text] [Related]
15. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
[TBL] [Abstract][Full Text] [Related]
16. ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes.
Vogel U; Nexø BA; Tjønneland A; Wallin H; Hertel O; Raaschou-Nielsen O
Mutat Res; 2006 Jan; 593(1-2):88-96. PubMed ID: 16054657
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R; Liang X; Yu JJ; Reed E
Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
